FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
Ocugen Inc OCGN
$1.23
▼ -2.38%
($-0.03)
🔥 High Short Interest
🎢 High Beta
📅 Earnings This Week
Open
$1.29
Prev Close
$1.26
Day Range
$1.23 – $1.30
52W Range
$0.93 – $2.73
Market Cap
$416.38M
Beta
2.17
EPS (TTM)
$-0.18
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-12-03 |
| Shares Out. | 338,520,000 |
| Website | ocugen.com/ ↗ |
| Phone | 13026587581 |
| Employees | 116 |
| Revenue | $1.5M |
| Gross Profit | $1.5M |
| Net Income | -$19.2M |
| Free Cash Flow | -$59.6M |
| Total Assets | $56.9M |
| Total Liabilities | $51.1M |
| Equity | $5.8M |
About Ocugen Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ocugen Inc is a publicly traded company under the ticker symbol OCGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)